Branaplam


Branaplam is an experimental drug being developed by Novartis to treat spinal muscular atrophy. It is a pyridazine derivative that works by increasing the amount of functional survival of motor neuron protein produced by the SMN2 gene through modifying its splicing pattern.
, branaplam is in a phase-II clinical trial in children with SMA type 1.
of branaplam